<DOC>
	<DOCNO>NCT00903617</DOCNO>
	<brief_summary>This two part study ( Part A Part B ) first aim establish PK/PD relationship exposure lipid effect ( Part A : 75 subject ) , confirm effect use relevant dose ( ) ( Part B : ~90 subject ) . Doses 5mg , 50mg 150mg GSK256073 administer Part A , dose ( ) Part B base PK/PD data Part A . Data Part A Part B combine decrease overall subject number need part B . Part B study include niaspan arm relative comparison effect GSK256073 niacin lipid flush</brief_summary>
	<brief_title>Study Test GSK256073 Patients With Dyslipidemia</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Signed write informed consent prior begin studyrelated procedure . Subjects must understand aim , investigational procedure possible consequence study must able understand comply protocol requirement , instruction protocolstated restriction . Male female 1875 year age screening . A female subject eligible participate nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea . Male subject must agree use one several prespecified contraception method . This criterion must follow time first dose study medication three day follow last dose . Body weight &gt; 50 kg ( 110 pound ) body mass index ( BMI ) 19 39 ( inclusive ) LDLc concentration ≥100 mg/dL screen within 4 week randomization ( screen occurs &gt; 4 week prior randomization ) Fasting triglyceride concentration ≤ 300 mg/dL screen within 4 week randomization ( screen occurs &gt; 4 week prior randomization ) HDLc ≤ 45 mg/dL male ≤ 55 mg/dL female screen within 4 week randomization ( screen occurs &gt; 4 week prior randomization ) Subject currently receive lipidmodifying medication ( ) must agree stop medication ( ) least 6 week prior randomization . After washout period LDL , TG HDL value must remeasured meet criterion prior randomization study AST ALT &lt; 2xULN ; alkaline phosphatase bilirubin ≤ 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Evidence clinical instability base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk interfere study procedure . Any change concomitant medication ( include multivitamin , herbal remedy , dietary supplement , overthecounter medication ) within six week prior screen approve GSK . Any change diet , exercise habit smoke status within six week prior screen . A medical history significant following : Clinical cardiovascular disease , include history current evidence coronary heart disease , heart failure , cerebrovascular disease , peripheral vascular disease , and/or 10year risk CHD &gt; 20 % titrate lipid lower medication . Subjects pending diagnostic procedure condition time screen eligible participation . Renal impairment ( male ) define calculated GFR &lt; 60 mL/min . Renal impairment ( female ) define calculated GFR &lt; 55 ml/min . History diabetes mellitus , history postprandial and/or random blood glucose &gt; 200 mg/dl fast glucose &gt; 125 mg/dL currently take diabetes medication manage fast glucose level ( e.g . glitazones , sulfonylurea , insulin , metformin , etc. ) . History anemia treatment anemia within 12 month screen Hgb Hct low limit reference range age gender screen History pancreatitis Any concurrent serious illness ( e.g. , severe COPD , HIV positive , liver cirrhosis , history malignancy skin cancer within 5 year initial diagnosis evidence recurrence ) may interfere subject complete study Active peptic ulcer disease ( PUD ) and/or history PUD gastrointestinal bleeding within 12 month prior screen . History kidney stone History gout and/or hyperuricemia take drug hyperuricemia : allopurinol and/or probenecid History Gilbert 's syndrome Current inadequately control hypertension ( blood pressure ≥160 mmHg systolic ≥100 mmHg diastolic screening ) . If blood pressure medication change , blood pressure remeasured 6 week must meet criterion . An unwillingness subject currently take aspirin reduce daily dose 81 mg start 2 week prior first dose followup visit . Creatinine phosphokinase ( CPK ) 2X ULN screening . A serum uric acid exceed ≥ 15 % upper limit reference range screening . PT and/or aPTT reference range . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . The subject positive prestudy drug screen . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids benzodiazepine . History regular alcohol consumption within 6 month study define : An average weekly intake &gt; 14 drinks/week men &gt; 7 drinks/week woman . One drink equivalent ( 12 g alcohol ) = 5 ounce ( 150 ml ) wine 12 ounce ( 360 ml ) beer 1.5 ounce ( 45 ml ) 80 proof distil spirit . Use follow blood pressure medication prohibit dose : enalapril , losartan , captopril If subject titrate switch alternative therapy must stable dose least 4 week prior randomization . Subjects exclude require treatment systemic corticosteroid Subjects excluded take quinolone antibiotic , methotrexate , ibuprofen medication secrete renal OAT transporter Treatment investigational drug within 30 day 5 halflives ( whichever longer ) prior dose Exposure four new chemical entity within 12 month prior first dose day History sensitivity untoward reaction study medication ( i.e . GSK256073 Niaspan ) , component thereof history drug allergy , opinion physician responsible , contraindicate participation Where participation study would result donation blood excess 500 mL within 56 day period . A positive test HIV antibody . Subject mentally legally incapacitate . Unwillingness inability follow procedure outline protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>lipid</keyword>
	<keyword>HM74A</keyword>
</DOC>